GILEAD SCIENCES SL
- Country
- 🇺🇸United States
- Ownership
- -
- Established
- 1994-01-01
- Employees
- -
- Market Cap
- $95.8B
Safety, Pharmacodynamics, Pharmacokinetics, and Efficacy of GS-9901 in Adults With Relapsed or Refractory Follicular Lymphoma, Marginal Zone Lymphoma, Chronic Lymphocytic Leukemia, or Small Lymphocytic Lymphoma
- Conditions
- Follicular LymphomaChronic Lymphocytic LeukemiaMarginal Zone LymphomaSmall Lymphocytic Lymphoma
- Interventions
- First Posted Date
- 2014-10-07
- Last Posted Date
- 2015-10-19
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 7
- Registration Number
- NCT02258555
- Locations
- 🇺🇸
Innovative Clinical Research Institute, Whittier, California, United States
🇺🇸Cancer Center Central Connecticut, Southington, Connecticut, United States
🇺🇸Lombardi Cancer Center-Georgetown University, Washington, District of Columbia, United States
Idelalisib in Combination With Rituximab for Previously Untreated Follicular Lymphoma and Small Lymphocytic Lymphoma
- Conditions
- Small Lymphocytic LymphomaFollicular Lymphoma
- Interventions
- Biological: Rituximab
- First Posted Date
- 2014-10-07
- Last Posted Date
- 2019-05-14
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 10
- Registration Number
- NCT02258529
- Locations
- 🇺🇸
Pacific Shores Medical Group, Long Beach, California, United States
🇺🇸Prarie Lakes Health Care Systems, Inc., Watertown, South Dakota, United States
🇺🇸St. Agnes Hospital, Baltimore, Maryland, United States
Presatovir in Hematopoietic Cell Transplant Recipients With Respiratory Syncytial Virus Infection of the Upper Respiratory Tract
- First Posted Date
- 2014-10-01
- Last Posted Date
- 2018-08-06
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 189
- Registration Number
- NCT02254408
- Locations
- 🇺🇸
City of Hope, Duarte, California, United States
🇧🇷Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil
🇧🇷Hospital Universitario USP, Sao Paulo, Brazil
Presatovir in Hematopoietic Cell Transplant Recipients With Respiratory Syncytial Virus (RSV) Infection of the Lower Respiratory Tract
- Conditions
- Respiratory Syncytial Virus Infection
- Interventions
- Drug: Placebo
- First Posted Date
- 2014-10-01
- Last Posted Date
- 2018-09-24
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 60
- Registration Number
- NCT02254421
- Locations
- 🇨🇭
University Clinical Basel, Basel, Switzerland
🇺🇸Medical College of Wisconsin, Milwaukee, Wisconsin, United States
🇺🇸University of Minnesota, Minneapolis, Minnesota, United States
Safety and Efficacy of Ledipasvir/Sofosbuvir (LDV/SOF) Fixed Dose Combination (FDC) for 12 or 24 Weeks in Kidney Transplant Recipients With Chronic HCV Infection
- Conditions
- Hepatitis C Virus Infection
- Interventions
- Drug: LDV/SOF
- First Posted Date
- 2014-09-29
- Last Posted Date
- 2018-11-19
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 114
- Registration Number
- NCT02251717
Development of a Patient-Reported Outcome Measure to Assess Symptoms in Patients With Primary Sclerosing Cholangitis (PSC)
- Conditions
- Primary Sclerosing Cholangitis
- First Posted Date
- 2014-09-25
- Last Posted Date
- 2016-02-09
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 26
- Registration Number
- NCT02247934
- Locations
- 🇺🇸
University of Colorado Hospital, Denver Health Medical Center, Aurora, Colorado, United States
🇺🇸University of Miami Miller School of Medicine - Schiff Center for Liver Diseases, Miami, Florida, United States
🇺🇸Duke University Medical Center, Durham, North Carolina, United States
Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed Dose Combination +/- Ribavirin in Adolescents and Children With Chronic HCV-Infection
- First Posted Date
- 2014-09-25
- Last Posted Date
- 2020-03-02
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 226
- Registration Number
- NCT02249182
Renal Effect of Stribild or Other Tenofovir DF-containing Regimens Compared to Ritonavir-boosted Atazanavir Plus Abacavir/Lamivudine in Antiretroviral Treatment-naive HIV-1 Infected Adults
- Conditions
- HIV-1 Infection
- Interventions
- First Posted Date
- 2014-09-23
- Last Posted Date
- 2018-01-03
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 72
- Registration Number
- NCT02246998
Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Idelalisib in Japanese Participants With Relapsed or Refractory Indolent B-Cell Non-Hodgkin Lymphomas (iNHL) or Chronic Lymphocytic Leukemia (CLL)
- Conditions
- Marginal Zone LymphomaChronic Lymphocytic LeukemiaIndolent Non-Hodgkin LymphomaLymphoplasmacytic Lymphoma (With or Without Waldenstrom Macroglobulinemia)Follicular LymphomaSmall Lymphocytic Lymphoma
- Interventions
- First Posted Date
- 2014-09-16
- Last Posted Date
- 2021-03-19
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 6
- Registration Number
- NCT02242045
Selonsertib in Adults With Pulmonary Arterial Hypertension
- Conditions
- Pulmonary Arterial Hypertension
- Interventions
- Drug: Placebo
- First Posted Date
- 2014-09-09
- Last Posted Date
- 2019-04-10
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 151
- Registration Number
- NCT02234141
- Locations
- 🇺🇸
VA Greater Los Angeles Healthcare System, Los Angeles, California, United States
🇨🇦University Health Network, Toronto, Ontario, Canada
🇺🇸University of Minnesota, Minneapolis, Minnesota, United States